Medicines Co. at sector perform by RBC

RBC Capital Markets analyst Jason Kantor gave The Medicines Co. a sector perform, above average risk, rating and a $24 price target. Testimony is underway regarding U.S. House Resolution 5120 that could provide the company with a patent extension of 4.5 years for Angiomax. The analyst believes the bill will move forward. This is a positive catalyst, according to the analyst, not previously forecasted by investors. Shares of the Parsippany, N.J.-based pharmaceutical company were down 11 cents, or 0.49%, at $22.57. (Nasdaq: MDCO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.